Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 13-18 , May 2009

Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ): Initial Discovery and Subsequent Development

  • Salvatore L. Ruggiero, DMD, MD

      Affiliations

    • New York Center for Oral and Maxillofacial Surgery, Lake Success, NY
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Ruggiero: New York Center for Oral and Maxillofacial Surgery, 2001 Marcus Avenue, Suite N10, Lake Success, NY 11042

References 

  1. Blomen L. History of Bisphosphonates: Discovery and History of the Non-medicaluses of Bisphosphonates. Amsterdam: Elsevier Science Publishers; 1995;
  2. Fleisch H, Russell R, Francis M. Diphosphonates inhibit hydroxyapetite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 1969;165:1262
  3. Francis M, Russell R, Fleisch H. Diphosphonate inhibit formation of calcium phosphate crystals in vitro and pathological calcifications in vivo. Science. 1969;165:1264
  4. Berensen J, Lichtenstein A, Porter L. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334:484
  5. Hortobagyi G, Theriualt R, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastasis. N Engl J Med. 1996;335:1785
  6. Reid I, Nicholson G, Weinstein R, et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial. Am J Med. 1996;101:341
  7. Rosen L, Gordon D, Kaminski M, et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III double-blind comparative trial. Cancer. 2001;7:377
  8. Rosen L, Gordon D, Tchekmedyian S, et al. Zolendronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blinded randomized trial. J Clin Oncol. 2003;21:3150
  9. Saad F, Gleason D, Murray R, et al. A randomized, placebo-controlled trial of zolendronic acid in patients with hormone-refractory metastatic prostate carconoma. J Natl Cancer Inst. 2002;94:1458
  10. Berenson J, Hillner B, Kyle R, et al. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719
  11. Hillner B, Ingle J, Berenson J. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol. 2000;18:1378
  12. Hoff A. Osteonecrosis of the jaw in patients receiving bisphosphonate therapy. J Bone Miner Res. 2005;20:
  13. Ruggiero S, Gralow J, Marx R, et al. Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer. J Clin Oncol Prac. 2006;2:7
  14. FDA. Bisphosphonates and Oral Osteonecrosis. Washington, DC: FDA; 2007;
  15. Edwards B, Gounder M, McKoy J, et al. Bisphosphonate use and osteonecrosis of the jaw: Pharmacovigilence and reporting of this serious adverse event. Lancet Oncol. 2009;(in press)
  16. Felton J. Classic syndromes in occupational medicine (Phosphorus necrosis: A classical occupational disease). Am J Indust Med. 1982;3:77
  17. Hellstein J, Marek C. Bis-phossy jaw, phossy jaw and the 21st century: Bisphosphonate-associated complication of the jaws. J Oral Maxillofac Surg. 2004;62:1563
  18. Marx R, Stern D. Oral and Maxillofacial Pathology: A Rationale for Diagnosis and Treatment (Vol 1). Chicago, IL: Quintessence Publishing Co; 2000;
  19. Mehrotra B, Fantasia J, Nissel-Horowitz S, et al. Osteonecrosis of the maxilla: An unusual complication of prolonged bisphosphonate therapy (A case report). (abstract 3194) Proc Am Soc Clin Oncol. 2003;22:795
  20. Marx R. Pamidronate (Aredia) and zolendronate (Zometa) induced vascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 2003;61:1115
  21. Rosenberg T, Ruggiero S. Osteonecrosis of the jaws associated with the use of bisphosphonates. J Oral Maxillofac Surg. 2003;61(suppl 1):
  22. Ruggiero S, Mehrotra B, Rosenberg T. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004;62:
  23. Durie B, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates (letter). N Engl J Med. 2005;353:99
  24. Bone H, Hosking D, Devogelaer J, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189
  25. Mavrokokki T, Cheng A, Stein B, et al. The nature and incidence of bisphosphonate associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;3:415
  26. Bamias A, Efstathios K, Bamia C, et al. Osteonecrosis of the jaw in cancer patients after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol. 2005;23:8580
  27. Dimopoulos M, Kastritis E, Moulopoulos L. The incidence of osteonecrosis of the jaw in patients with multiple myeloma who receive bisphosphonates depends on the type of bisphosphonate (abstract). Blood. 2005;106:637
  28. Cafro A, Barbarano L, Andriani A. Osteonecrosis of the jaw associated with chronic bisphosphonate therapy: An Italian experience (abstract). Blood. 2005;106:5152
  29. Tossi P, Zamagni E, Cangini D. Bisphosphonates and osteonecrosis of the jaws: Incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zolendronic acid (abstract). Blood. 2005;106:3461
  30. Pozzi S, Marcheselli R, Sacchi S. Analysis of frequency and risk factors for developing bisphosphonate associated necrosis of the jaw (abstract). Blood. 2005;106:5057
  31. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society of Bone and Mineral Research. J Bone Miner Res. 2007;22:1479
  32. Dimopoulos M, Kastritis E, Bamia C, et al. Decreased incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid after application of preventive measures. Blood. 2007;110:1056A
  33. Badros A, Evangelos T, Goloubeva O, et al. Long-term follow-up of multiple myeloma patients with osteonecrosis of the jaw. Blood. 2007;110:1030A
  34. Mehrotra B, Fantasia J, Ruggiero S. Outcomes of bisphosphonate related osteonecrosis of the jaw (Importance of staging and management guidelines. A large single institutional update). J Clin Oncol. 2008;26:322

 Dr Ruggiero is a paid consultant for Amgen Corporation and Procter and Gamble and has received honorarium from Novartis.

PII: S0278-2391(08)01629-7

doi: 10.1016/j.joms.2008.10.005

Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 13-18 , May 2009

Article Tools

* Image Usage & Resolution